Wessler Benjamin S, Kent David M
Predictive Analytics and Comparative Effectiveness (PACE) Center, Institute for Clinical Research and Health Policy Studies (ICRHPS), Tufts Medical Center/Tufts University School of Medicine, 800 Washington St, Box 63, Boston, MA, 02111, USA.
Curr Treat Options Cardiovasc Med. 2015 Jan;17(1):358. doi: 10.1007/s11936-014-0358-6.
Cardioembolic (CE) stroke mechanisms account for a significant number of ischemic strokes; however, the true burden is likely underestimated. It is critically important to identify patients with CE strokes because these individuals have high recurrence rates and represent a subgroup of patients who may benefit from targeted therapy in the form of anticoagulation or device based treatments. Current guidelines offer recommendations for diagnosis and treatment of these patients; however, important questions remain. First, appropriate cardiac testing in the setting of CE must be individualized and the optimal duration of electrocardiographic monitoring to rule out atrial fibrillation (AF) is unclear. Second, risk stratification tools for AF remain understudied, and there is controversy about which anticoagulant agents are most appropriate. Lastly, important potential CE sources of stroke such as patent foramen ovale have garnered significant attention recently, and debate regarding how to manage these patients persists. In this review, we discuss some of the important controversies in diagnosing and treating patients with possible CE stroke, pointing to areas where future research might be particularly valuable.
心源性栓塞(CE)性卒中机制在大量缺血性卒中中占相当比例;然而,其真正负担可能被低估。识别CE性卒中患者至关重要,因为这些个体复发率高,且代表了可能从抗凝或基于器械治疗等靶向治疗中获益的患者亚组。当前指南为这些患者的诊断和治疗提供了建议;然而,重要问题依然存在。首先,CE情况下的适当心脏检查必须个体化,且排除心房颤动(AF)的最佳心电图监测时长尚不清楚。其次,AF的风险分层工具仍未得到充分研究,对于哪种抗凝剂最合适存在争议。最后,诸如卵圆孔未闭等重要的潜在CE性卒中来源最近受到了极大关注,关于如何处理这些患者的争论仍在持续。在本综述中,我们讨论了诊断和治疗可能为CE性卒中患者时的一些重要争议,指出了未来研究可能特别有价值的领域。